This document is a publication of a United States Patent and Trademark Office (USPTO) patent application, specifically US20260083724A1, filed by Georgetown University. The application describes compounds designed to bind to and reduce the levels of the PAX3::FOXO1 fusion protein, which is implicated in fusion-positive rhabdomyosarcoma (FP-RMS). The invention includes a binding moiety, a linker, and an E3 ubiquitin ligase binding moiety, with potential applications in treating FP-RMS and diseases caused by PAX3::FOXO1 overexpression.

As this is a patent application publication, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signifies potential future developments in pharmaceutical research and development for rhabdomyosarcoma treatments. Companies involved in oncology drug development, particularly those researching targeted protein degradation therapies, should note this application as it may impact the intellectual property landscape and future therapeutic strategies in this area.